Global Ganja Report

The Justice Department and Drug Enforcement Administration announced April 23 that FDA-approved marijuana products and medical marijuana products covered by a qualifying state-issued license have been moved to Schedule III of the Controlled Substances Act, a significant loosening of federal restrictions on the drug for medical use.

The order, issued by Acting Attorney General Todd Blanche, carries out President Donald Trump's Dec. 18, 2025 executive order calling for expanded research into medical marijuana and cannabidiol.

It was federal subsidies for healthcare that were center-stage in the government shutdown and the Capitol Hill deal that finally ended it. But the fight over the heretofore ambiguous legal status of hemp-derived THC was also at issue in the end—and this could represent a serious blow to America’s farmers.

In a last-minute move before the measure was to automatically become law, Gov. Greg Abbott on June 23 vetoed Senate Bill 3, which sought to ban the sale of all THC-laden products in Texas, whether Delta-8 and Delta-9. The bill would have also placed greater restrictions on CBD products, such as banning their sale to those under 21. Abbott has called for a special legislative session to revisit the question, which has pitted the hemp industry against the GOP establishment. Abbott's own Lt. Gov. Dan Patrick was a key advocate of the "THC ban." Patrick bashed Abbott over the veto, saying he "wants to legalize recreational marijuana."

In the big — and, in nearly half of US states now, successful — drive to legalize cannabis, two major arguments have been brought to bear. First, that public oversight of a legal industry will assure transparency and standards for quality. And secondly, that a taxed industry will be a boon to state and local economies.

But now a disturbing new study from an industry advocacy group in California indicates that the legal cannabis sector faces a challenge in the proliferation of ostensibly legal but in fact unregulated psychoactive “hemp” products.

In the ultimate imprimatur of mainstream acceptance, the 10th annual Cannabis World Congress & Business Expo was held June 5-6 in Manhattan’s Javits Convention Center, the Big Apple’s premier venue for trade shows and industry confabs. And the event had the open participation of New York city and state government agencies, as well as capitalist enterprises from around the country and the planet.

Israel is an emerging player in the international cannabis market, and the industry is embraced by pillars of the country’s political establishment. But every aspect of Israeli society as been impacted by the horrific events of last October 7, and the ensuing war. The cannabis sector has been no exception.

Small producers have long been wary of the cannabis industry coming under domination by multi-state operators with the worst practices of corporate America. But the revelations of Russian oligarch money in the coffers of leading MSO Curaleaf appear to vindicate even the most cynical observers. These follow a slew of controversies concerning product safety and labor rights at the company.

The arrival of a major US multi-state operator in Bangkok is a sign of the global cannabis industry's big ambitions for Thailand, the first Asian country to decriminalize. But with enabling legislation still pending, the regulatory environment remains uncertain.